Diabetes Patient Advocacy Coalition, Inc. – Trademark Portfolio

Entity Type: 99

Diabetes Patient Advocacy Coalition, Inc. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 4 filings in this category. Currently, 4 trademarks are registered. Notable registered marks include DPAC and DIABETES PATIENT ADVOCACY COALITION. The owner is based in Lexington, KY.

229 Tahoma Road

Lexington, KY 40503

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Diabetes Patient Advocacy Coalition, Inc.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

35
Advertising & Business (4 filings)

Advertising; business management; business administration; office functions

Frequently Asked Questions

How many trademarks does Diabetes Patient Advocacy Coalition, Inc. have?

Diabetes Patient Advocacy Coalition, Inc. has 4 U.S. trademarks filed with the USPTO. Of these, 4 registered.

What trademark classes does Diabetes Patient Advocacy Coalition, Inc. file in?

Diabetes Patient Advocacy Coalition, Inc. files trademarks across 1 Nice Classification class. The most active classes are Class 35 (Advertising & Business). Class 35 covers advertising; business management; business administration; office functions.

What are Diabetes Patient Advocacy Coalition, Inc.'s most well-known trademarks?

Diabetes Patient Advocacy Coalition, Inc.'s registered trademark portfolio includes well-known marks such as DPAC and DIABETES PATIENT ADVOCACY COALITION. These are among 4 currently registered trademarks in the portfolio.

What is Diabetes Patient Advocacy Coalition, Inc.'s trademark registration success rate?

Diabetes Patient Advocacy Coalition, Inc. has a 100% trademark registration rate, with 4 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.